ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Biologicals
Volume 35, Issue 2, April 2007, Pages 79-97
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (489 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.biologicals.2007.01.002    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2007 The International Association for Biologicals Published by Elsevier Ltd.

Review

Impact of vCJD on blood supply

Rainer Seitza, Corresponding Author Contact Information, E-mail The Corresponding Author, Friedger von Auerb, Johannes Blümela, Reinhard Burgerc, Anne Buschmannd, Klaus Dietze, Margarethe Heidena, Walter E. Hitzlerf, Horst Klammb, Thomas Kreilg, Hans Kretzschmarh, Micha Nüblinga, Ruth Offergeldc, Georg Paulic, Volkmar Schottstedti, Peter Volkersa and Inga Zerrj

aPaul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51–59, D-63225 Langen, Germany bFederal Ministry of Health, Bonn, Germany cRobert Koch-Institut, Berlin, Germany dFriedrich-Loeffler-Institut, Insel Riems, Germany eDepartment of Medical Biometry, Eberhard-Karls-University, Tübingen, Germany fTransfusion Centre, Johannes Gutenberg-University Hospital, Mainz, Germany gBaxter AG, Vienna, Austria hCentre for Neuropathology and Prion Research, Ludwig-Maximilians-University, Munich, Germany iGerman Red Cross Blood Donation Service West, Hagen, Germany jDepartment of Neurology, Prion Research Group, University Hospital, Göttingen, Germany

Received 16 November 2006; 
revised 9 January 2007; 
accepted 9 January 2007. 
Available online 21 February 2007.


Referred to by:Blood-transmitted prions and variant Creutzfeldt–Jakob disease
BiologicalsVolume 35, Issue 2April 2007, Pages 75-77
George F. Grady, Girish N. Vyas
PDF (88 K)
Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Variant Creutzfeldt–Jakob disease (vCJD) is an at present inevitably lethal neurodegenerative disease which can only be diagnosed definitely post mortem. The majority of the approximately 200 victims to date have resided in the UK where most contaminated beef materials entered the food chain. Three cases in the UK demonstrated that vCJD can be transmitted by blood transfusion. Since BSE and vCJD have spread to several countries outside the UK, it appears advisable that specific risk assessments be carried out in different countries and geographic areas. This review explains the approach adopted by Germany in assessing the risk and considering precautionary measures. A fundamental premise is that the feeding chain of cattle and the food chain have been successfully and permanently cleared from contaminated material. This raises the question of whether transmissions via blood transfusions could have the potential to perpetuate vCJD in mankind. A model calculation based on actual population data showed, however, that this would not be the case. Moreover, an exclusion of transfusion recipients from blood donation would add very little to the safety of blood transfusions, but would have a considerable impact on blood supply. Therefore, an exclusion of transfusion recipients was not recommended in Germany.

Keywords: Bovine spongiform encephalopathy; Variant Creutzfeldt–Jakob disease; Blood supply; Risk assessment

Abbreviations: AFSSAPS, Agence Française de Sécurité Sanitaire des Produits de Santé (French medicinal products authority); BSE, bovine spongiform encephalopathy (degenerative neurological disease in cattle caused by prions); CJD, Creutzfeldt–Jakob disease (TSE disease in humans, transmissible via medicinal products (iatrogenic) or occurring sporadically); FFP, “fresh frozen plasma”(plasma for transfusion); GBR, “geographical BSE risk”: classification of countries into one of four risk classes (GBR I–IV) by the Scientific Steering Committee of the European Commission; GSS, Gerstmann-Sträussler-Scheinker syndrome (a human TSE); HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus (agent of AIDS); i.c., intracerebral; IU, infectious unit; i.v., intravenous; M, methionine; PMCA, protein misfolding cyclic amplification (method for amplification of PrPSc in vitro); PrP, prion protein; PrPc, cellular, physiological form of the prion protein (c = cellular); PrPSc, pathological form of the prion protein (Sc = Scrapie); RBCC, red blood cell concentrate; SCMPMD, Scientific Committee on Medicinal Products and Medical Devices of the European Commission; SRM, specified risk material (bovine materials in which the BSE agent can be detected in high concentrations (brain, spinal cord etc.)); SSC, Scientific Steering Committee of the European Commission; TSE, transmissible spongiform encephalopathy (disease of the brain, generic term for neurological disorders caused by prions); UK, United Kingdom (Great Britain and Northern Ireland); V, valine; vCJD, variant Creutzfeldt–Jakob disease (human TSE caused by the BSE agent, first described in 1996)

Article Outline

1. Introduction
2. The Occurrence of BSE
3. BSE in Germany
4. BSE in small ruminants
5. The occurrence of vCJD
6. Estimation of the extent of the spread of vCJD
7. Risk of vCJD transmission through blood (secondary infections)
8. Reduction of TSE in the manufacture of blood products
9. Blood components for transfusion, leukocyte depletion
9.1. Red blood cell concentrates (RBCC)
9.2. Platelet concentrates (PC)
9.3. Plasma for transfusion (“Fresh Frozen Plasma, FFP”)
10. Industrial products from pool plasma, nanofiltration
10.1. Effectiveness of the plasma fractionation steps
10.2. Nanofiltration
11. Optimal use of blood products
12. Diagnosing vCJD: screening tests
13. Exclusion of persons from donating blood
14. Impact of deferrals on the blood supply
15. Summary and conclusions
Acknowledgements
References







Biologicals
Volume 35, Issue 2, April 2007, Pages 79-97
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.